NDC 0093-3064 Aspirin And Dipyridamole

Aspirin And Dipyridamole

NDC Product Code 0093-3064

NDC Code: 0093-3064

Proprietary Name: Aspirin And Dipyridamole What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Aspirin And Dipyridamole What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Product Characteristics

Color(s):
ORANGE (C48331 - SWEDISH ORANGE)
WHITE (C48325)
Shape: CAPSULE (C48336)
Size(s):
23 MM
Imprint(s):
TEVA;3064;TEVA;3064
Score: 1

NDC Code Structure

  • 0093 - Teva Pharmaceuticals Usa, Inc.
    • 0093-3064 - Aspirin And Dipyridamole

NDC 0093-3064-06

Package Description: 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE

NDC Product Information

Aspirin And Dipyridamole with NDC 0093-3064 is a a human prescription drug product labeled by Teva Pharmaceuticals Usa, Inc.. The generic name of Aspirin And Dipyridamole is aspirin and dipyridamole. The product's dosage form is capsule, extended release and is administered via oral form.

Labeler Name: Teva Pharmaceuticals Usa, Inc.

Dosage Form: Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Aspirin And Dipyridamole Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • ASPIRIN 25 mg/1
  • DIPYRIDAMOLE 200 mg/1

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • ALUMINUM MONOSTEARATE (UNII: P9BC99461E)
  • SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
  • COPOVIDONE K25-31 (UNII: D9C330MD8B)
  • STARCH, CORN (UNII: O8232NY3SJ)
  • HYPROMELLOSE 2208 (100 MPA.S) (UNII: B1QE5P712K)
  • HYPROMELLOSE 2208 (4000 MPA.S) (UNII: 39J80LT57T)
  • HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
  • HYPROMELLOSE 2910 (3 MPA.S) (UNII: 0VUT3PMY82)
  • HYPROMELLOSE 2910 (50 MPA.S) (UNII: 1IVH67816N)
  • HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST) (UNII: G4U024CQK6)
  • LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
  • LECITHIN, SOYBEAN (UNII: 1DI56QDM62)
  • MALTODEXTRIN (UNII: 7CVR7L4A2D)
  • METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) (UNII: 5KY68S2577)
  • MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
  • POVIDONE K25 (UNII: K0KQV10C35)
  • POVIDONE K90 (UNII: RDH86HJV5Z)
  • POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
  • DIMETHICONE (UNII: 92RU3N3Y1O)
  • TALC (UNII: 7SEV7J4R1U)
  • TARTARIC ACID (UNII: W4888I119H)
  • TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
  • TRIACETIN (UNII: XHX3C3X673)
  • XANTHAN GUM (UNII: TTV12P4NEE)
  • GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
  • FERRIC OXIDE RED (UNII: 1K09F3G675)
  • WATER (UNII: 059QF0KO0R)
  • D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
  • FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
  • FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
  • INDIGOTINDISULFONATE SODIUM (UNII: D3741U8K7L)
  • FD&C RED NO. 40 (UNII: WZB9127XOA)
  • FERROSOFERRIC OXIDE (UNII: XM0M87F357)
  • PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
  • SHELLAC (UNII: 46N107B71O)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
  • Decreased Prostaglandin Production - [PE] (Physiologic Effect)
  • Nonsteroidal Anti-inflammatory Compounds - [Chemical/Ingredient]
  • Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
  • Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)
  • Decreased Platelet Aggregation - [PE] (Physiologic Effect)
  • Decreased Platelet Aggregation - [PE] (Physiologic Effect)
  • Platelet Aggregation Inhibitor - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Teva Pharmaceuticals Usa, Inc.
Labeler Code: 0093
FDA Application Number: ANDA078804 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 06-10-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Aspirin And Dipyridamole Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

2 Dosage And Administration

Aspirin and extended-release dipyridamole is not interchangeable with the individual components of aspirin and dipyridamole tablets.The recommended dose of aspirin and extended-release dipyridamole is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. Aspirin and extended-release dipyridamole can be administered with or without food.

2.1 Alternative Regimen In Case Of Intolerable Headaches

In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.

3 Dosage Forms And Strengths

25 mg/200 mg: Two-piece hard gelatin capsule with a Swedish orange opaque cap and white opaque body, imprinted in black ink with TEVA over 3064 on the cap and TEVA over 3064 on the body.

4.1 Hypersensitivity

Aspirin and extended-release dipyridamole is contraindicated in patients with known hypersensitivity to any of the product components.

4.2 Allergy

Aspirin is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug (NSAID) products and in patients with the syndrome of asthma, rhinitis, and nasal polyps. Aspirin may cause severe urticaria, angioedema or bronchospasm.

4.3 Reye Syndrome

Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome.

5.1 Risk Of Bleeding

Aspirin and extended-release dipyridamole increases the risk of bleeding. Risk factors for bleeding include the use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, heparin, anagrelide, fibrinolytic therapy, and chronic use of NSAIDs) [see Drug Interactions (7.1)].Intracranial HemorrhageIn European Stroke Prevention Study-2 (ESPS2), the incidence of intracranial hemorrhage was 0.6% in the aspirin and extended-release dipyridamole group, 0.5% in the extended-release dipyridamole (ER-DP) group, 0.4% in the aspirin (ASA) group and 0.4% in the placebo groups.Gastrointestinal (GI) Side EffectsGI side effects include stomach pain, heartburn, nausea, vomiting, and gross GI bleeding. Although minor upper GI symptoms, such as dyspepsia, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and bleeding, even in the absence of previous GI symptoms. Inform patients about the signs and symptoms of GI side effects and what steps to take if they occur.In ESPS2 the incidence of gastrointestinal bleeding was 4.1% in the aspirin and extended-release dipyridamole group, 2.2% in the extended-release dipyridamole group, 3.2% in the aspirin group, and 2.1% in the placebo groups.Peptic Ulcer DiseaseAvoid using aspirin in patients with a history of active peptic ulcer disease, which can cause gastric mucosal irritation and bleeding.Alcohol WarningBecause aspirin and extended-release dipyridamole contains aspirin, counsel patients who consume three or more alcoholic drinks every day about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.

5.2 Renal Failure

Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/minute) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

5.3 Hepatic Insufficiency

Elevations of hepatic enzymes and hepatic failure have been reported in association with dipyridamole administration [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

5.4 Pregnancy

Because aspirin and extended-release dipyridamole contains aspirin, aspirin and extended-release dipyridamole can cause fetal harm when administered to a pregnant woman. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence for intracranial hemorrhage in premature infants, stillbirths and neonatal death. Because of the above and because of the known effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the fetal cardiovascular system (closure of the ductus arteriosus), avoid aspirin and extended-release dipyridamole in the third trimester of pregnancy [see Use in Specific Populations (8.1)].Aspirin has been shown to be teratogenic in rats (spina bifida, exencephaly, microphthalmia and coelosomia) and rabbits (congested fetuses, agenesis of skull and upper jaw, generalized edema with malformation of the head, and diaphanous skin) at oral doses of 330 mg/kg/day and 110 mg/kg/day, respectively. These doses, which also resulted in a high resorption rate in rats (63% of implantations versus 5% in controls), are, on a mg/m2 basis, about 66 and 44 times, respectively, the dose of aspirin contained in the maximum recommended daily human dose of aspirin and extended-release dipyridamole. Reproduction studies with dipyridamole have been performed in mice, rabbits and rats at oral doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. When 330 mg aspirin/kg/day was combined with 75 mg dipyridamole/kg/day in the rat, the resorption rate approached 100%, indicating potentiation of aspirin-related fetal toxicity. There are no adequate and well-controlled studies of the use of aspirin and extended-release dipyridamole in pregnant women. If aspirin and extended-release dipyridamole is used during pregnancy, or if the patient becomes pregnant while taking aspirin and extended-release dipyridamole, inform the patient of the potential hazard to the fetus.

5.5 Coronary Artery Disease

Dipyridamole has a vasodilatory effect. Chest pain may be precipitated or aggravated in patients with underlying coronary artery disease who are receiving dipyridamole.For stroke or TIA patients for whom aspirin is indicated to prevent recurrent myocardial infarction (MI) or angina pectoris, the aspirin in this product may not provide adequate treatment for the cardiac indications.

5.6 Hypotension

Dipyridamole produces peripheral vasodilation, which can exacerbate pre-existing hypotension.

5.7 General

Aspirin and extended-release dipyridamole capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets.

6 Adverse Reactions

  • The following adverse reactions are discussed elsewhere in the labeling:Hypersensitivity [see Contraindications (4.1)]Allergy [see Contraindications (4.2)]Risk of Bleeding [see Warnings and Precautions (5.1)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The efficacy and safety of aspirin and extended-release dipyridamole was established in the European Stroke Prevention Study-2 (ESPS2). ESPS2 was a double-blind, placebo-controlled study that evaluated 6602 patients over the age of 18 years who had a previous ischemic stroke or transient ischemic attack within ninety days prior to entry. Patients were randomized to either aspirin and extended-release dipyridamole, aspirin, ER-DP, or placebo [see Clinical Studies (14)]; primary endpoints included stroke (fatal or nonfatal) and death from all causes.This 24-month, multicenter, double-blind, randomized study (ESPS2) was conducted to compare the efficacy and safety of aspirin and extended-release dipyridamole with placebo, extended- release dipyridamole alone and aspirin alone. The study was conducted in a total of 6602 male and female patients who had experienced a previous ischemic stroke or transient ischemia of the brain within three months prior to randomization.Table 1 presents the incidence of adverse events that occurred in 1% or more of patients treated with aspirin and extended-release dipyridamole where the incidence was also greater than in those patients treated with placebo. There is no clear benefit of the dipyridamole/aspirin combination over aspirin with respect to safety.Table 1 Incidence of Adverse Events in ESPS21Individual Treatment GroupAspirin andExtended-Release DipyridamoleER-DP AloneASAAlonePlaceboBody System/Preferred Term1650165416491649Total Number of PatientsTotal Number (%) of Patients With at Least One On-Treatment Adverse Event1319(80%)1305(79%)1323(80%)1304(79%)Central and Peripheral Nervous System Disorders Headache647(39%)634(38%)558(34%)543(33%) Convulsions28(2%)15(1%)28(2%)26(2%)Gastrointestinal System Disorders Dyspepsia303(18%)288(17%)299(18%)275(17%) Abdominal Pain289(18%)255(15%)262(16%)239(14%) Nausea264(16%)254(15%)210(13%)232(14%) Diarrhea210(13%)257(16%)112(7%)161(10%) Vomiting138(8%)129(8%)101(6%)118(7%) Hemorrhage Rectum26(2%)22(1%)16(1%)13(1%) Melena31(2%)10(1%)20(1%)13(1%) Hemorrhoids16(1%)13(1%)10(1%)10(1%) GI Hemorrhage20(1%)5(0%)15(1%)7(0%)Body as a Whole – General Disorders Pain105(6%)88(5%)103(6%)99(6%) Fatigue95(6%)93(6%)97(6%)90(5%) Back Pain76(5%)77(5%)74(4%)65(4%) Accidental Injury42(3%)24(1%)51(3%)37(2%) Malaise27(2%)23(1%)26(2%)22(1%) Asthenia29(2%)19(1%)17(1%)18(1%) Syncope17(1%)13(1%)16(1%)8(0%)Psychiatric Disorders Amnesia39(2%)40(2%)57(3%)34(2%) Confusion18(1%)9(1%)22(1%)15(1%) Anorexia19(1%)17(1%)10(1%)15(1%) Somnolence20(1%)13(1%)18(1%)9(1%)Musculoskeletal System Disorders Arthralgia91(6%)75(5%)91(6%)76(5%) Arthritis34(2%)25(2%)17(1%)19(1%) Arthrosis18(1%)22(1%)13(1%)14(1%) Myalgia20(1%)16(1%)11(1%)11(1%)Respiratory System Disorders Coughing25(2%)18(1%)32(2%)21(1%) Upper Respiratory Tract Infection16(1%)9(1%)16(1%)14(1%)Cardiovascular Disorders, General Cardiac Failure26(2%)17(1%)30(2%)25(2%)Platelet, Bleeding and Clotting Disorders Hemorrhage NOS52(3%)24(1%)46(3%)24(1%) Epistaxis39(2%)16(1%)45(3%)25(2%) Purpura23(1%)8(0%)9(1%)7(0%)Neoplasm Neoplasm NOS28(2%)16(1%)23(1%)20(1%)Red Blood Cell Disorders Anemia27(2%)16(1%)19(1%)9(1%)1. Reported by ≥1% of patients during aspirin and extended-release dipyridamole treatment where the incidence was greater than in those treated with placebo.Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.NOS = not otherwise specified.Discontinuation due to adverse events in ESPS2 was 25% for aspirin and extended-release dipyridamole, 25% for extended-release dipyridamole, 19% for aspirin, and 21% for placebo (refer to Table 2)Table 2 Incidence of Adverse Events that Led to the Discontinuation of Treatment: Adverse Events with an Incidence of ≥1% in the Aspirin and Extended-Release Dipyridamole GroupTreatment GroupsAspirin andExtended-Release DipyridamoleER-DP ASAPlaceboTotal Number of Patients1650165416491649Patients with at least one Adverse Event that led to treatment discontinuation417(25%)419(25%)318(19%)352(21%)Headache165(10%)166(10%)57(3%)69(4%)Dizziness85(5%)97(6%)69(4%)68(4%)Nausea91(6%)95(6%)51(3%)53(3%)Abdominal Pain74(4%)64(4%)56(3%)52(3%)Dyspepsia59(4%)61(4%)49(3%)46(3%)Vomiting53(3%)52(3%)28(2%)24(1%)Diarrhea35(2%)41(2%)9(<1%)16(<1%)Stroke39(2%)48(3%)57(3%)73(4%)Transient Ischemic Attack35(2%)40(2%)26(2%)48(3%)Angina Pectoris23(1%)20(1%)16(<1%)26(2%)Note: ER-DP = extended-release dipyridamole 200 mg; ASA = aspirin 25 mg. The dosage regimen for all treatment groups is BID.Headache was most notable in the first month of treatment.Other Adverse EventsAdverse reactions that occurred in less than 1% of patients treated with aspirin and extended-release dipyridamole in the ESPS2 study and that were medically judged to be possibly related to either dipyridamole or aspirin are listed below.Body as a Whole: Allergic reaction, feverCardiovascular: HypotensionCentral Nervous System: Coma, dizziness, paresthesia, cerebral hemorrhage, intracranial hemorrhage, subarachnoid hemorrhageGastrointestinal: Gastritis, ulceration and perforationHearing and Vestibular Disorders: Tinnitus, and deafness. Patients with high frequency hearing loss may have difficulty perceiving tinnitus. In these patients, tinnitus cannot be used as a clinical indicator of salicylismHeart Rate and Rhythm Disorders: Tachycardia, palpitation, arrhythmia, supraventricular tachycardiaLiver and Biliary System Disorders: Cholelithiasis, jaundice, hepatic function abnormalMetabolic and Nutritional Disorders: Hyperglycemia, thirstPlatelet, Bleeding and Clotting Disorders: Hematoma, gingival bleedingPsychiatric Disorders: AgitationReproductive: Uterine hemorrhageRespiratory: Hyperpnea, asthma, bronchospasm, hemoptysis, pulmonary edemaSpecial Senses Other Disorders: Taste lossSkin and Appendages Disorders: Pruritus, urticaria Urogenital: Renal insufficiency and failure, hematuria Vascular (Extracardiac) Disorders: FlushingLaboratory ChangesOver the course of the 24-month study (ESPS2), patients treated with aspirin and extended-release dipyridamole showed a decline (mean change from baseline) in hemoglobin of 0.25 g/dL, hematocrit of 0.75%, and erythrocyte count of 0.13x106/mm3.

6.2 Post-Marketing Experience

The following is a list of additional adverse reactions that have been reported either in the literature or are from post-marketing spontaneous reports for either dipyridamole or aspirin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to aspirin and extended-release dipyridamole.Body as a Whole: Hypothermia, chest painCardiovascular: Angina pectorisCentral Nervous System: Cerebral edemaFluid and Electrolyte: Hyperkalemia, metabolic acidosis, respiratory alkalosis, hypokalemiaGastrointestinal: Pancreatitis, Reye syndrome, hematemesisHearing and Vestibular Disorders: Hearing lossImmune System Disorders: Hypersensitivity, acute anaphylaxis, laryngeal edemaLiver and Biliary System Disorders: Hepatitis, hepatic failureMusculoskeletal: Rhabdomyolysis Metabolic and Nutritional Disorders: Hypoglycemia, dehydrationPlatelet, Bleeding and Clotting Disorders: Prolongation of the prothrombin time, disseminated intravascular coagulation, coagulopathy, thrombocytopeniaReproductive: Prolonged pregnancy and labor, stillbirths, lower birth weight infants, antepartum and postpartum bleedingRespiratory: Tachypnea, dyspneaSkin and Appendages Disorders: Rash, alopecia, angioedema, Stevens-Johnson syndrome, skin hemorrhages such as bruising, ecchymosis, and hematomaUrogenital: Interstitial nephritis, papillary necrosis, proteinuriaVascular (Extracardiac) Disorders: Allergic vasculitisOther Adverse Events: anorexia, aplastic anemia, migraine, pancytopenia, thrombocytosis.

7.1 Drug Interaction Study Information Obtained From Literature

AdenosineDipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.Angiotensin Converting Enzyme (ACE) InhibitorsDue to the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.AcetazolamideConcurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.Anticoagulants and AntiplateletsPatients taking aspirin and extended-release dipyridamole in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk.AnagrelidePatients taking aspirin in combination with anagrelide are at an increased risk of bleeding.AnticonvulsantsSalicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels.Beta BlockersThe hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.Cholinesterase InhibitorsDipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.DiureticsThe effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.MethotrexateSalicylate can inhibit renal clearance of methotrexate, leading to bone marrow toxicity, especially in the elderly or renal impaired.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)The concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function.Oral HypoglycemicsModerate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia.Uricosuric Agents (probenecid and sulfinpyrazone)Salicylates antagonize the uricosuric action of uricosuric agents.

8.1 Pregnancy

Teratogenic Effects, Pregnancy Category D [see Warnings and Precautions (5.4)].

8.2 Labor And Delivery

Aspirin can result in excessive blood loss at delivery as well as prolonged gestation and prolonged labor. Because of these effects on the mother and because of adverse fetal effects seen with aspirin during the later stages of pregnancy [see Warnings and Precautions (5.4)], avoid aspirin and extended-release dipyridamole in the third trimester of pregnancy and during labor and delivery.

8.3 Nursing Mothers

Both dipyridamole and aspirin are excreted in human milk. Exercise caution when aspirin and extended-release dipyridamole capsules are administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of aspirin and extended-release dipyridamole in pediatric patients have not been studied. Due to the aspirin component, use of this product in the pediatric population is not recommended [see Contraindications (4.3)].

8.5 Geriatric Use

Of the total number of subjects in ESPS2, 61 percent were 65 and over, while 27 percent were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].

8.6 Patients With Severe Hepatic Or Severe Renal Dysfunction

Aspirin and extended-release dipyridamole has not been studied in patients with hepatic or renal impairment. Avoid using aspirin containing products, such as aspirin and extended-release dipyridamole in patients with severe hepatic or severe renal (glomerular filtration rate <10 mL/min) dysfunction [see Warnings and Precautions (5.2, 5.3) and Clinical Pharmacology (12.3)].

10 Overdosage

Because of the dose ratio of dipyridamole to aspirin, overdosage of aspirin and extended-release dipyridamole is likely to be dominated by signs and symptoms of dipyridamole overdose. In case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential.Based upon the known hemodynamic effects of dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed.Salicylate toxicity may result from acute ingestion (overdose) or chronic intoxication. Severity of aspirin intoxication is determined by measuring the blood salicylate level. The early signs of salicylic overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approaching 200 mcg/mL. In severe cases, hyperthermia and hypovolemia are the major immediate threats to life. Plasma concentrations of aspirin above 300 mcg/mL are clearly toxic. Severe toxic effects are associated with levels above 400 mcg/mL. A single lethal dose of aspirin in adults is not known with certainty but death may be expected at 30 g.Treatment of overdose consists primarily of supporting vital functions, increasing drug elimination, and correcting acid-base disturbances. Consider gastric emptying and/or lavage as soon as possible after ingestion, even if the patient has vomited spontaneously. After lavage and/or emesis, administration of activated charcoal as a slurry may be beneficial if less than 3 hours have passed since ingestion. Charcoal absorption should not be employed prior to emesis and lavage. Follow acid-base status closely with serial blood gas and serum pH measurements. Maintain fluid and electrolyte balance. Administer replacement fluid intravenously and augment with correction of acidosis. Treatment may require the use of a vasopressor. Infusion of glucose may be required to control hypoglycemia.Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Plasma electrolytes and pH should be monitored serially to promote alkaline diuresis of salicylate if renal function is normal. In patients with renal insufficiency or in cases of life-threatening intoxication, dialysis is usually required to treat salicylic overdose; however, since dipyridamole is highly protein bound, dialysis is not likely to remove dipyridamole. Exchange transfusion may be indicated in infants and young children.

11 Description

Aspirin and Extended-Release Dipyridamole Capsules are a combination antiplatelet agent intended for oral administration. Each hard gelatin capsule contains 200 mg dipyridamole in an extended-release form and 25 mg aspirin, as an immediate-release sugar-coated tablet. In addition, each capsule contains the following inactive ingredients: aluminum monostearate, colloidal silicon dioxide, copovidone, corn starch, hypromellose, hypromellose phthalate, lactose monohydrate, lecithin, maltodextrin, methacrylic acid copolymer, microcrystalline cellulose, povidone, polyethylene glycol, simethicone, talc, tartaric acid, titanium dioxide, triacetin and xanthan gum. Each capsule shell also contains gelatin, red iron oxide and water. The imprinting ink contains D&C yellow no. 10 aluminum lake, FD&C blue no. 1 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, iron oxide black, propylene glycol and shellac glaze.DipyridamoleDipyridamole is an antiplatelet agent chemically described as 2,2',2'',2'''-[(4,8- Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:C24H40N8O4 M.W. 504.63Dipyridamole is an odorless yellow crystalline substance, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and is practically insoluble in water.AspirinThe antiplatelet agent aspirin (acetylsalicylic acid) is chemically known as benzoic acid, 2- (acetyloxy)-, and has the following structural formula:C9H8O4 M.W. 180.16Aspirin is an odorless white needle-like crystalline or powdery substance. When exposed to moisture, aspirin hydrolyzes into salicylic and acetic acids, and gives off a vinegary odor. It is highly lipid soluble and slightly soluble in water.

12.1 Mechanism Of Action

The antithrombotic action of aspirin and extended-release dipyridamole is the result of the additive antiplatelet effects of dipyridamole and aspirin.DipyridamoleDipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to 1.9 mcg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP).Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of dipyridamole inhibit cyclic-3',5'‑ guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide).AspirinAspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction.

12.2 Pharmacodynamics

The effect of either agent on the other's inhibition of platelet reactivity has not been evaluated.

12.3 Pharmacokinetics

There are no significant interactions between aspirin and dipyridamole. The kinetics of the components are unchanged by their co-administration as aspirin and extended-release dipyridamole.DipyridamoleAbsorptionPeak plasma levels of dipyridamole are achieved 2 hours (range 1 to 6 hours) after administration of a daily dose of 400 mg aspirin and extended-release dipyridamole (given as 200 mg BID). The peak plasma concentration at steady-state is 1.98 mcg/mL (1.01 to 3.99 mcg/mL) and the steady-state trough concentration is 0.53 mcg/mL (0.18 to 1.01 mcg/mL).Effect of FoodWhen aspirin and extended-release dipyridamole capsules were taken with a high fat meal, dipyridamole peak plasma levels (Cmax) and total absorption (AUC) were decreased at steady-state by 20 to 30% compared to fasting. Due to the similar degree of inhibition of adenosine uptake at these plasma concentrations, this food effect is not considered clinically relevant.DistributionDipyridamole is highly lipophilic (log P=3.71, pH=7); however, it has been shown that the drug does not cross the blood-brain barrier to any significant extent in animals. The steady-state volume of distribution of dipyridamole is about 92 L. Approximately 99% of dipyridamole is bound to plasma proteins, predominantly to alpha 1-acid glycoprotein and albumin.Metabolism and EliminationDipyridamole is metabolized in the liver, primarily by conjugation with glucuronic acid, of which monoglucuronide which has low pharmacodynamic activity is the primary metabolite. In plasma, about 80% of the total amount is present as parent compound and 20% as monoglucuronide. Most of the glucuronide metabolite (about 95%) is excreted via bile into the feces, with some evidence of enterohepatic circulation. Renal excretion of parent compound is negligible and urinary excretion of the glucuronide metabolite is low (about 5%). With intravenous (i.v.) treatment of dipyridamole, a triphasic profile is obtained: a rapid alpha phase, with a half-life of about 3.4 minutes, a beta phase, with a half-life of about 39 minutes, (which, together with the alpha phase accounts for about 70% of the total area under the curve, AUC) and a prolonged elimination phase λz with a half-life of about 15.5 hours. Due to the extended absorption phase of the dipyridamole component, only the terminal phase is apparent from oral treatment with aspirin and extended-release dipyridamole which, in Trial 9.123 was 13.6 hours.Special PopulationsGeriatric Patients: In ESPS2 [see Clinical Studies (14)], plasma concentrations (determined as AUC) of dipyridamole in healthy elderly subjects (>65 years) were about 40% higher than in subjects younger than 55 years receiving treatment with aspirin and extended-release dipyridamole.Hepatic Dysfunction: No study has been conducted with aspirin and extended-release dipyridamole in patients with hepatic dysfunction.In a study conducted with an intravenous formulation of dipyridamole, patients with mild to severe hepatic insufficiency showed no change in plasma concentrations of dipyridamole but showed an increase in the pharmacologically inactive monoglucuronide metabolite. Dipyridamole can be dosed without restriction as long as there is no evidence of hepatic failure.Renal Dysfunction: No study has been conducted with aspirin and extended-release dipyridamole in patients with renal dysfunction.In ESPS2 patients [see Clinical Studies (14)], with creatinine clearances ranging from about 15 mL/min to >100 mL/min, no changes were observed in the pharmacokinetics of dipyridamole or its glucuronide metabolite if data were corrected for differences in age.AspirinAbsorptionPeak plasma levels of aspirin are achieved 0.63 hours (0.5 to 1 hour) after administration of a 50 mg aspirin daily dose from aspirin and extended-release dipyridamole (given as 25 mg BID). The peak plasma concentration at steady-state is 319 ng/mL (175 to 463 ng/mL). Aspirin undergoes moderate hydrolysis to salicylic acid in the liver and the gastrointestinal wall, with 50% to 75% of an administered dose reaching the systemic circulation as intact aspirin.Effect of FoodWhen aspirin and extended-release dipyridamole capsules were taken with a high fat meal, there was no difference for aspirin in AUC at steady-state, and the approximately 50% decrease in Cmax was not considered clinically relevant based on a similar degree of cyclooxygenase inhibition comparing the fed and fasted state.DistributionAspirin is poorly bound to plasma proteins and its apparent volume of distribution is low (10 L). Its metabolite, salicylic acid, is highly bound to plasma proteins, but its binding is concentration-dependent (nonlinear). At low concentrations (<100 mcg/mL), approximately 90% of salicylic acid is bound to albumin. Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and fetal tissues. Early signs of salicylate overdose (salicylism), including tinnitus (ringing in the ears), occur at plasma concentrations approximating 200 mcg/mL [see Adverse Reactions (6) and Overdosage (10)].Metabolism and EliminationAspirin is rapidly hydrolyzed in plasma to salicylic acid, with a half-life of 20 minutes. Plasma levels of aspirin are essentially undetectable 2 to 2.5 hours after dosing and peak salicylic acid concentrations occur 1 hour (range: 0.5 to 2 hours) after administration of aspirin. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites. Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. Following toxic doses (10 to 20 g), the plasma half-life may be increased to over 20 hours.The elimination of acetylsalicylic acid follows first-order kinetics with aspirin and extended-release dipyridamole and has a half-life of 0.33 hours. The half-life of salicylic acid is 1.71 hours. Both values correspond well with data from the literature at lower doses which state a resultant half-life of approximately 2 to 3 hours. At higher doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher. Renal excretion of unchanged drug depends upon urinary pH. As urinary pH rises above 6.5, the renal clearance of free salicylate increases from <5% to >80%. Alkalinization of the urine is a key concept in the management of salicylate overdose [see Overdosage (10)]. Following therapeutic doses, about 10% is excreted as salicylic acid and 75% as salicyluric acid, as the phenolic and acyl glucuronides, in urine.Special PopulationsHepatic Dysfunction: Avoid aspirin in patients with severe hepatic insufficiency.Renal Dysfunction: Avoid aspirin in patients with severe renal failure (glomerular filtration rate less than 10 mL/min).Aspirin and Extended-Release DipyridamoleDrug InteractionA dedicated drug interaction study was conducted in 60 healthy volunteers to evaluate the effects of omeprazole 80 mg administered once daily on the pharmacokinetics (PK) of dipyridamole and the pharmacodynamics (PD) of acetylsalicylic acid when co-administered with aspirin and extended-release dipyridamole twice daily. Dipyridamole exposure (Cmax and AUC) at steady-state were similar with or without omeprazole co-administration. The pharmacokinetics of acetylsalicylic acid was not characterized. However, the antiplatelet activity as measured by arachidonic acid induced platelet aggregation was similar between the treatment arms at steady-state.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

In studies in which dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m2 basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats.Combinations of dipyridamole and aspirin (1:5 ratio) tested negative in the Ames test, in vivo chromosome aberration tests (in mice and hamsters), oral micronucleus tests (in mice and hamsters) and oral dominant lethal test (in mice). Aspirin, alone, induced chromosome aberrations in cultured human fibroblasts. Mutagenicity tests of dipyridamole alone with bacterial and mammalian cell systems were negative.Combinations of dipyridamole and aspirin have not been evaluated for effects on fertility and reproductive performance. There was no evidence of impaired fertility when dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m2 basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m2 basis). Aspirin inhibits ovulation in rats.

14 Clinical Studies

ESPS2 (European Stroke Prevention Study 2) was a double-blind, placebo-controlled, 24-month study in which 6602 patients over the age of 18 years had an ischemic stroke (76%) or transient ischemic attack (TIA, 24%) within three months prior to entry. Patients were enrolled in 13 European countries between February 1989 and May 1995 and were randomized to one of four treatment groups: Aspirin and extended-release dipyridamole 25 mg/200 mg; extended-release dipyridamole (ER-DP) 200 mg alone; aspirin (ASA) 25 mg alone; or placebo. The mean age in this population was 66.7 years with 58% of them being males. Patients received one capsule twice daily (morning and evening). Efficacy assessments included analyses of stroke (fatal or nonfatal) and death (from all causes) as confirmed by a blinded morbidity and mortality assessment group. There were no differences with regard to efficacy based on age or gender; patients who were older had a trend towards more events.Stroke EndpointAspirin and extended-release dipyridamole reduced the risk of stroke by 22.1% compared to aspirin 50 mg/day alone (p = 0.008) and reduced the risk of stroke by 24.4% compared to extended- release dipyridamole 400 mg/day alone (p = 0.002) (Table 3). Aspirin and extended-release dipyridamole reduced the risk of stroke by 36.8% compared to placebo (p <0.001).Table 3 Summary of First Stroke (Fatal or Nonfatal): ESPS2: Intent-to-Treat PopulationTotal Number of PatientsnNumber of Patients WithStroke Within 2 Yearsn (%)Kaplan-Meier Estimate of Survival at 2 Years (95% C.I.)Gehan-Wilcoxon Test P-valueRisk Reduction at 2 YearsOdds Ratio (95% C.I.)Individual Treatment GroupAspirin and Extended-Release Dipyridamole1650157 (9.5%)89.9% (88.4%, 91.4%)---ER-DP1654211 (12.8%)86.7% (85.0%, 88.4%)---ASA1649206 (12.5%)87.1% (85.4%, 88.7%)---Placebo1649250 (15.2%)84.1% (82.2%, 85.9%)---Pairwise Treatment Group ComparisonsAspirin and Extended-Release Dipyridamole vs.ER-DP---0.002124.4%0.72 (0.58, 0.90)Aspirin and Extended-Release Dipyridamole vs.ASA---0.008122.1%0.74 (0.59, 0.92)Aspirin and Extended-Release Dipyridamole vs.Placebo---<0.001136.8%0.59 (0.48, 0.73)ER-DP vs. Placebo---0.036216.5%0.82 (0.67, 1.00)ASA vs. Placebo---0.009118.9%0.80 (0.66, 0.97)1. p-value ≤0.0102. 0.010

16 How Supplied/Storage And Handling

Aspirin and Extended-Release Dipyridamole Capsules are available as:25 mg/200 mg: Two-piece hard gelatin capsule with a Swedish orange opaque cap and white opaque body. Imprinted in black ink with TEVA over 3064 on the cap and TEVA over 3064 on the body and available in unit-of-use bottles of 60 capsules (NDC 0093-3064-06).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Protect from excessive moisture.KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

17 Patient Counseling Information

  • Advise the patient to read the FDA-approved patient labeling (Patient Information).Risk of BleedingInform patients that as with other antiplatelet agents, there is a general risk of bleeding including intracranial and gastrointestinal bleeding. Inform patients about the signs and symptoms of bleeding, including occult bleeding. Tell patients to notify their physician if they are prescribed any drug which may increase risk of bleeding.Counsel patients who consume three or more alcoholic drinks daily about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.PregnancyInform patients that aspirin is known to be harmful to fetuses and ask the patient to notify them if they are or become pregnant.HeadachesSome patients may experience headaches upon treatment initiation; these are usually transient. In case of intolerable headaches, tell patients to contact their physician.Dosage and AdministrationTell patients that aspirin and extended-release dipyridamole capsules should be swallowed whole, and not chewed or crushed. If you miss a dose, continue with your next dose on your regular schedule. Do not take a double dose.StorageInform patients to protect aspirin and extended-release dipyridamole from moisture.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 8/2016

Patient Information

  • Aspirin and Extended-Release DipyridamoleCapsulesRead this Patient Information before you start taking aspirin and extended-release dipyridamole capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.What is aspirin and extended-release dipyridamole?Aspirin and extended-release dipyridamole is a prescription medicine that contains aspirin and a medicine that is slowly released in your body, called dipyridamole. Aspirin and extended-release dipyridamole is used to lower the risk of stroke in people who have had a “mini-stroke” (transient ischemic attack or TIA) or stroke due to a blood clot.It is not known if aspirin and extended-release dipyridamole is safe and effective in children. See “Who should not take aspirin and extended-release dipyridamole?”Who should not take aspirin and extended-release dipyridamole? Do not take aspirin and extended-release dipyridamole if you:are allergic to any of the ingredients in aspirin and extended-release dipyridamole. See the end of this leaflet for a list of ingredients in aspirin and extended-release dipyridamole.are allergic to non-steroidal anti-inflammatory drugs (NSAIDs)have asthma in combination with runny nose and nasal polypsDo not give aspirin and extended-release dipyridamole to a child or teenager with a viral illness. Reye syndrome, a life-threatening condition, can happen when aspirin (an ingredient in aspirin and extended-release dipyridamole) is used in children and teenagers who have certain viral illnesses.What should I tell my doctor before using aspirin and extended-release dipyridamole? Before taking aspirin and extended-release dipyridamole, tell your healthcare provider if you:have stomach ulcershave a history of bleeding problemshave heart problemshave kidney or liver problemshave low blood pressurehave myasthenia gravishave any other medical conditionsare pregnant or plan to become pregnant. Aspirin and extended-release dipyridamole can harm your unborn baby, especially if you take it in the last (third) trimester of pregnancy. You should not take aspirin and extended-release dipyridamole during pregnancy without first talking to your healthcare provider. Tell your healthcare provider right away if you become pregnant while taking aspirin and extended-release dipyridamole.are breast-feeding or plan to breast-feed. Aspirin and extended-release dipyridamole can pass into your milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take aspirin and extended-release dipyridamole.Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Aspirin and extended-release dipyridamole and other medicines may affect each other causing side effects. Aspirin and extended-release dipyridamole may affect the way other medicines work, and other medicines may affect how aspirin and extended-release dipyridamole works.Especially tell your healthcare provider if you take:a medicine for high blood pressure, irregular heart beat, or heart failureacetazolamide [Diamox®]any blood thinner medicineswarfarin sodium [Coumadin®, Jantoven®]a heparin medicineanagrelide (Agrylin®)a seizure medicinea medicine for Alzheimer’s diseasea water pillmethotrexate sodium [Trexall®]aspirin or a non-steroidal anti-inflammatory drug (NSAIDs). You should not take NSAIDs during treatment with aspirin and extended-release dipyridamole. Using these medicines with aspirin and extended-release dipyridamole can increase your risk of bleeding.a medicine for diabetesprobenecid [Probalan®, Col-Probenecid®]Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above.Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist when you get a new medicine.How should I take aspirin and extended-release dipyridamole?Take aspirin and extended-release dipyridamole capsules exactly as prescribed. Your healthcare provider will tell you how many aspirin and extended-release dipyridamole capsules to take and when to take them.Headaches are not uncommon when you first start taking aspirin and extended-release dipyridamole, but often lessen as treatment continues. Tell your healthcare provider if you have a severe headache. Your healthcare provider may change the instructions for taking aspirin and extended-release dipyridamole.Swallow aspirin and extended-release dipyridamole capsules whole. Do not crush or chew the capsules.You can take aspirin and extended-release dipyridamole with or without food.If you miss a dose, take your next dose at the usual time. Do not take two doses at one time.If you take more aspirin and extended-release dipyridamole (overdose) than prescribed, call your healthcare provider or Poison Control Center, or get emergency help right away.Symptoms of an overdose of aspirin and extended-release dipyridamole include:a warm feeling or flushingsweatingrestlessnessweakness or dizzinessa fast heart rateringing in the earsWhat should I avoid while using aspirin and extended-release dipyridamole?heavy alcohol use. People who drink three or more alcoholic drinks every day have a higher risk of bleeding during treatment with aspirin and extended-release dipyridamole, because it contains aspirin.What are the possible side effects of aspirin and extended-release dipyridamole? Aspirin and extended-release dipyridamole may cause serious side effects, including:increased risk of bleeding. You may bleed more easily during aspirin and extended-release dipyridamole treatment, and it may take longer than usual for bleeding to stop. This can include:bleeding into your brain (intracranial hemorrhage). This can be a medical emergency. Get medical help right away if you have any of these symptoms while taking aspirin and extended-release dipyridamole:severe headache with drowsinessconfusion or memory changepass out (become unconscious)bleeding in your stomach or intestine.stomach painheartburn or nauseavomiting blood or vomit looks like “coffee grounds”red or bloody stoolsblack stools that look like tarnew or worsening chest pain in some people with heart disease. Tell your healthcare provider if you have new chest pain or have any change in your chest pain during treatment with aspirin and extended-release dipyridamole.liver problems, including increased liver function tests and liver failure. Tell your healthcare provider if you have any of these symptoms of a liver problem while taking aspirin and extended-release dipyridamole:loss of appetitepale colored stoolstomach area (abdomen) painyellowing of your skin or whites of your eyesdark urineitchingCall your healthcare provider right away if you have any of the symptoms listed above.The most common side effects of aspirin and extended-release dipyridamole include:headacheupset stomachdiarrheaThese are not all the possible side effects of aspirin and extended-release dipyridamole. Tell your healthcare provider or pharmacist if you have any side effect that bothers you or that does not go away.Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA- 1088.How should I store aspirin and extended-release dipyridamole?Store aspirin and extended-release dipyridamole at 68°F to 77°F (20°C to 25°C).Keep aspirin and extended-release dipyridamole capsules dry.Safely throw away medicine that is out of date or no longer needed.Keep aspirin and extended-release dipyridamole and all medicines out of the reach of children. General information about aspirin and extended-release dipyridamoleMedicines are sometimes prescribed for purposes other than those listed in the Patient Information. Do not use aspirin and extended-release dipyridamole for a condition for which it was not prescribed. Do not give aspirin and extended-release dipyridamole to other people, even if they have the same symptoms that you have. It may harm them.This Patient Information summarizes the most important information about aspirin and extended-release dipyridamole. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about aspirin and extended-release dipyridamole that is written for health professionals. For more information about aspirin and extended-release dipyridamole capsules call 1-888-838-2872. What are the ingredients in aspirin and extended-release dipyridamole capsules?Active Ingredients: dipyridamole in an extended-release form and aspirinInactive Ingredients: aluminum monostearate, colloidal silicon dioxide, copovidone, corn starch, hypromellose, hypromellose phthalate, lactose monohydrate, lecithin, maltodextrin, methacrylic acid copolymer, microcrystalline cellulose, povidone, polyethylene glycol, simethicone, talc, tartaric acid, titanium dioxide, triacetin and xanthan gum. Each capsule shell also contains gelatin, red iron oxide and water. The imprinting ink contains D&C yellow no. 10 aluminum lake, FD&C blue no. 1 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, iron oxide black, propylene glycol and shellac glaze.All brand names listed are the registered trademarks of their respective owners and are not trademarks of Teva Pharmaceuticals USA.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Iss. 11/2015

Package/Label Display Panel

NDC 0093-3064-06Aspirin and Extended-Release Dipyridamole Capsules25 mg/200 mgRx only60 CAPSULES (unit-of-use)TEVA

* Please review the disclaimer below.

Previous Code
0093-3061
Next Code
0093-3066